SHELLY SMITH: Open Payments
NPI 1346210697 · ROYAL OAK, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,241 in 120 payments from 19 companies in 2025. Trend: 2023 $330 · 2024 $1,476 · 2025 $2,241
Food & beverage: $2,241
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 18 | $297 |
| Alkermes, Inc. | 11 | $265 |
| E.R. Squibb & Sons, L.L.C. | 9 | $235 |
| ABBVIE INC. | 11 | $199 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $162 |
| Vanda Pharmaceuticals Inc. | 9 | $158 |
| Collegium Pharmaceutical, Inc. | 7 | $142 |
| Neurocrine BioSciences, Inc. | 6 | $125 |
| Corium, LLC | 9 | $115 |
| Teva Pharmaceuticals USA, Inc. | 5 | $113 |
Products named: ARISTADA, REXULTI, COBENFY, VRAYLAR, CAPLYTA, Jornay PM, INGREZZA, Azstarys.
Industry payments across MI — which companies pay providers there.
